Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Scipher picks up Chemomab’s liver disease drug via merger
Precision immunology company Scipher Medicine will absorb Chemomab after identifying the Israeli biotech’s liver disease drug as the ideal fit.
James Waldron
Jul 8, 2026 9:26am
Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline
Jul 6, 2026 5:10am
United Therapeutics pays $140M for thymic cell therapy startup
Jul 3, 2026 5:49am
Ipsen pens €700M deal to buy Swiss biotech for rare disease drug
Jul 1, 2026 8:05am
Ipsen inks $1.7B deal to buy Kartos for potential Jakafi add-on
Jun 29, 2026 8:03am
Scancell bids for Nasdaq-listed Neuphoria to raise US profile
Jun 29, 2026 7:55am
